Fludarabine

• Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano… Recruiting
  2022-503140-41-00 Phase III 12 countries Iovance Biotherapeutics Inc.
• A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be… Recruiting
  2024-510778-26-00 Phase II 6 countries Iovance Biotherapeutics Inc.
• CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting
  2022-502405-15-01 Phase II 5 countries Klinikum Der Universitat Munchen AöR
• Randomized Evaluation of Treosulfan versus Melphalan conditioning fol-lowed by PTCY in Patients with AML and MDS undergoing allogeneic Trans… Recruiting
  2023-507879-21-00 Phase II 1 country Technische Universitat Dresden
• Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervou… Recruiting
  2025-521144-38-00 Phase II 2 countries Bristol-Myers Squibb Services Unlimited Company
• Clinical trial for the use of a humanized CART directed against BCMA (ARI0002h) in patients with newly diagnosed primary plasma cell leukemi… Recruiting
  2024-515053-21-00 Phase II 1 country Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…
• LATE-R trial. A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients with Lat… Recruiting
  2024-512835-53-00 Phase II 1 country Fundacion Geltamo
• Randomized Phase 2 study testing two conditioning regimen with a single prophylaxis of graft-versus-host disease by cyclophosphamide and met… Recruiting
  2023-509042-35-01 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy Recruiting
  2024-513601-31-00 Phase II 1 country Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…
• Study comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid l… Recruiting
  2023-504555-27-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busul… Recruiting
  2022-502019-12-00 Phase III 1 country Centre Hospitalier Universitaire De Nantes
• Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting
  2023-510433-29-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
• A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m… Ended
  2024-517020-18-00 Phase II 1 country Fundacion PETHEMA
• A study to investigate the efficacy and safety of OTL-203 in subjects with mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) compared w… Ended
  2022-500306-17-00 Phase III 2 countries Orchard Therapeutics (Europe) Limited
• Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to expre… Ended
  2024-515467-66-00 Phase II 1 country Fundacio Sant Joan De Deu
• This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with alre… Ended
  2023-509349-11-00 Phase III 13 countries Acerta Pharma B.V.
• A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy, and pharmacokinetics in newly diagnosed pediatr… Ended
  2023-509834-20-00 Phase II 6 countries Novartis Pharma AG
• Study of CC-97540 (BMS-986353), CD19-CAR T Cells, in Participants with Active SLE Despite Immunosuppressants (Breakfree-SLE) Halted
  2024-519278-37-00 Phase II 9 countries Celgene Corp.
• Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma Halted
  2023-510560-12-00 Phase II 1 country Fundacion Pethema
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501260-18-00 Phase II 7 countries Kite Pharma Inc.
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie… Ended
  2022-501261-46-00 Phase II 7 countries Kite Pharma Inc.
• A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial respon… Expired
  2022-502907-31-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori

Showing 1–22 of 22 trials